MedTrace Logo

A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute Leukemia/ Lymphoma

NCT05909527 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2026-03-17

No results posted yet for this study

Summary

This study is a single arm, non blind, randomized, single center study aimed at evaluating the safety, pharmacokinetic characteristics, and preliminary efficacy of CD7 CAR-T cell injection in r/r T-ALL/LBL subjects.

Conditions

  • T-Cell Acute Lymphocytic Leukemia

Interventions

BIOLOGICAL

CD7 CAR-T

A single infusion of autologous CD7 CAR-T cells administered intravenously

Sponsors & Collaborators

  • Guangzhou Bio-gene Technology Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Junfang Yang, Bachelor · Hebei Yanda Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
2 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-01
Primary Completion
2028-08-01
Completion
2028-08-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05909527 on ClinicalTrials.gov